About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Novartis (NYSE:NVS) to acquire Anthos Therapeutics for a total deal value of up to $3.1B, consisting of an upfront payment of $925M, with potential additional payments of up to $2.15B. Anthos ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics.

Swiss pharmaceutical giant Novartis said on Tuesday (Feb 11) it has agreed to acquire biopharma firm Anthos Therapeutics for ...

Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline.

The transaction, expected to close in the first half of this year, will cost Novartis $925 million upfront with potential ...

Novartis AG has agreed to acquire Anthos Therapeutics for $925 million as the European drug giant seeks to bolster its late-stage cardiovascular pipeline.

The Super Bowl tackled breast cancer awareness in a new Novartis Commercial featuring survivor and comedian Wanda Sykes.

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at ...

DHAKA, Feb 10, 2025 (BSS) - The writ petition regarding the transfer of shares of Novartis Bangladesh Limited has been ...

Following the court’s decision, writ petitioner Advocate Iktandar Hossain Hawlader told the media that he would move to another High Court bench for a hearing ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...